Redeye considers Polygiene’s Q3 figures to be mixed, with higher-than-expected revenues and gross ma...
Redeye comments on SHH’s Q3 2025 report. SSH reported a 6% year-over-year (Y/Y) growth, slightly low...
Sales -7% vs. ABGSCe at SEK 63m * International expansion weighs on earnings * Likely negative conse...
Redeye comments on Dynavox’s Q3 report released earlier this morning, which delivered solid results.
Redeye comments on Fractal Gaming Group’s Q3 2025 report, which came in soft on the headline figures...
Redeye comments on Teneo AI’s Q3 report showing roughly flat q/q ARR growth while the pipeline conti...
Redeye gives its initial take on Xvivo’s Q3 report.
* Sales -6% vs. cons, adj. EBITA -14% vs. cons * Continued growth in Poland and Habberstad * Consens...
Redeye provides its key takeaways from Cheffelo’s CMD and updates its estimates and valuation follow...
Relais' Q3 adjusted EBITA came in slightly below LSEG Data & Analytics consensus.
Redeye comments on Vertiseit’s Q3 report, showing slightly lower ARR growth than expected, while the...
* Return to growth in Q3 driven by both M&A and organic recovery * Enedo headwinds should be more th...
* '25e-'27e adj. EBITA up 12-5% * Encouraging efficiency improvements and strategic initiatives * Tr...
Active Biotechs styrelse har beslutat om nyemission av aktier för minst 70 mkr.
Redeye provides a preview of its estimates ahead of BICO’s Q3 results, scheduled for release on Nove...
